Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05660135

Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia

Sponsor: Daewoong Pharmaceutical Co. LTD.

View on ClinicalTrials.gov

Summary

This study is a large-scale, prospective, multi-center, and non-interventional observation study to observe blood pressure and blood lipid changes and safety during administration of olomax tablets for 24 weeks in hypertensive patients with dyslipidemia.

Official title: Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia: a Multi-center-database Real-world Study

Key Details

Gender

All

Age Range

19 Years - Any

Study Type

OBSERVATIONAL

Enrollment

4000

Start Date

2022-06-20

Completion Date

2025-12-31

Last Updated

2025-08-24

Healthy Volunteers

No

Interventions

DRUG

Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca

Olomax Tab 20/5/5mg Olomax Tab 20/5/10mg Olomax Tab 40/5/5mg Olomax Tab 40/5/10mg

Locations (1)

The Catholic University of Korea, Seoul ST. Mary's Hospital

Seoul, South Korea